Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program
Aisha T. Langford(University of Michigan), Ronald S. Go(Mayo Clinic), Eileen Dimond(National Cancer Institute), Worta McCaskill‐Stevens(National Cancer Institute), Diane St. Germain(National Cancer Institute), Angela Carrigan(Frederick National Laboratory for Cancer Research), Rebecca A. Enos(Emmes (United States)), Ken Resnicow(University of Michigan), Kathy Wilkinson(Billings Clinic), Andrea Denicoff(National Cancer Institute)
Cited by 134
Related Papers
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JAMA Oncology|2015|1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697